Coherus Oncology (CHRS) Income from Continuing Operations (2013 - 2026)
Coherus Oncology (CHRS) posted Income from Continuing Operations of 36935000.0 for Q1 2026, up 20.31% sequentially from 46347000.0 in Q4 2025, and up 22.07% YoY from 30256046.91 in Q1 2025.
Coherus Oncology (CHRS) Income from Continuing Operations (2013 - 2026) Analysis & Trends
Coherus Oncology has reported Income from Continuing Operations for 14 years, with the latest figure at 36935000.0 in Q1 2026.
- Quarterly Income from Continuing Operations rose 22.07% year-over-year to 36935000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 172661000.0 (up 11.88% YoY) and the FY2025 annual result came in at 183124000.0, up 15.03% from the prior year.
- Income from Continuing Operations advanced to 36935000.0 in Q1 2026 per CHRS's latest filing, from 46347000.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 36935000.0 in Q1 2026 and troughed at 96084000.0 in Q1 2022.
- A 5-year average of 56840235.29 and a median of 47599000.0 in 2024 frame the typical range for Income from Continuing Operations.
- The sharpest annual moves came in 2022 and 2023: Income from Continuing Operations plunged 124.9% in 2022, then surged 54.25% in 2023.
- Over 5 years, Income from Continuing Operations stood at 58870000.0 in 2022, then plunged by 35.3% to 79653000.0 in 2023, then surged by 42.13% to 46093000.0 in 2024, then fell by 0.55% to 46347000.0 in 2025, then advanced by 20.31% to 36935000.0 in 2026.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered 36935000.0, 46347000.0, and 44517000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Coherus Oncology | 221.39 Mn | 116.08 Mn | 10.07 Mn | -33.35 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -33.35 Mn |
| Mar 31, 2026 | -36.94 Mn |
| Dec 31, 2025 | -46.35 Mn |
| Sep 30, 2025 | -44.52 Mn |
| Jun 30, 2025 | -44.86 Mn |
| Mar 31, 2025 | -47.40 Mn |
| Dec 31, 2024 | -46.09 Mn |
| Sep 30, 2024 | -47.60 Mn |
| Jun 30, 2024 | -54.85 Mn |
| Mar 31, 2024 | -68.04 Mn |
| Dec 31, 2023 | -79.65 Mn |
| Sep 30, 2023 | -39.64 Mn |
| Jun 30, 2023 | -42.87 Mn |
| Mar 31, 2023 | -75.73 Mn |
| Dec 31, 2022 | -58.87 Mn |
| Sep 30, 2022 | -86.65 Mn |
| Jun 30, 2022 | -50.15 Mn |
| Mar 31, 2022 | -96.08 Mn |
| Dec 31, 2021 | -45.68 Mn |
| Sep 30, 2021 | -38.53 Mn |